Abstract Glioblastoma multiforme (GBM) is the most common brain cancer of middle aged Americans. Unfortunately, survival rates are typically less than.

Slides:



Advertisements
Similar presentations
Rhiana Lau MMG C174 Professor Simpson
Advertisements

RNA INTERFERENCE RNAI RELATION TO P53 USING RNAI TO SILENCE MUTANT P53 IN BLADDER CANCER CELLS & SIRNA BAR CODE SCREENING By: Chelsey Maag.
Analyzing the effects of a gene-specific siRNA on IL13R-α2 mRNA and protein levels in glioblastoma multiforme cells INTRODUCTION  RNA interference (RNAi)
Prostate cancer: early detection, monitoring and prognosis: Essex Biomedical Sciences Institute (EBSI) Elena Klenova, University of Essex the search for.
Introduction and Background Abstract Our research is directed towards determining which treatments for cancer are the most effective on a cellular level.
Signaling Pathways Produced By Combining DsRNA with Paclitaxal to treat Ovarian Cancer Switu Patel.
Construction, Transformation, and Prokaryote Expression of a Fused GFP and Mutant Human IL-13 Gene Sequence Lindsay Venditti, Department of Biological.
PDAM is frequently downregulated in oligodendroglial tumors and its knockdown by siRNA induces cisplatin resistance Ng Ho-Keung 吳浩強 The State Key Laboratory.
THE IN VITRO EFFECTS OF BRYOSTATIN-1 IN CONJUNCTION WITH TEMOZOLOMIDE ON U87MG HUMAN GLIOBLASTOMA MULTIFORME CELLS Stefani Fults, BA & Jeffrey P. Thompson,
Manufacture of Human Interleukin 13 Protein Using a Prokaryotic Expression System Ryan Rupp, York College of Pennsylvania, Department of Biological Sciences.
Transfection. What is transfection? Broadly defined, transfection is the process of artificially introducing nucleic acids (DNA or RNA) into cells, utilizing.
Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.
SiRNA-mediated Down-Regulation of Survivin Inhibits Bladder Cancer Cell Growth S. Fuessel, S.Ning, M. Kotzsch #, K. Kraemer, M. Kappler*, U. Schmidt, H.
Thitiporn Miiksombat 1, Narumol Bhummaphan 1, Teerakul Arpornsuwan 2 1 Student in Medical Technology Program, Faculty of Allied Health Sciences, Thammasat.
Quantification and DNA Sequencing of IL-13Rα1 and IL-13Rα2 On Various Cancer Cell Lines Erin Dolac, Department of.
Investigating the Glycosylation of Interleukin 13 Receptor Alpha 2 Protein Expressed in Cancerous and Non-cancerous Cell Lines Christopher R. Pope and.
Transfection.
SiRNA and Epigenetic Asma Siddique Saloom Aslam Syeda Zainab Ali.
Asiatic acid, a derivative of Centella asiatica, induced apoptosis and decreased levels of free Ca 2+ in A-375 human melanoma Jason Aloisio, Department.
CENTRE FOR BIOTECHNOLOGY
Signaling Pathways Produced By Combining DsRNA with Paclitaxal to treat Ovarian Cancer Switu Patel.
Inhibition of PDCD6 Induces Cell Proliferation and Reduces Apoptosis in Human Epithelial Ovarian Cancer Cells Yan Huang, Xiaohua Wu Department of Gynecology,
Vectors for RNAi.
Relationship Between STAT3 Inhibition and the Presence of p53 on Cyclin D1 Gene Expression in Human Breast Cancer Cell Lines Introduction STAT3 and p53.
Altogen Biosystems offers the Transfection Reagent for PANC-1 Cells Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection.
Products > B16-F10 Transfection Reagent (Mouse Melanoma Cells) Altogen Biosystems offers the B16-F10 Transfection Reagent among a host of 100+ cell line.
Products > 293T/17 Transfection Reagent (Embryonic Kidney Cells, CRL-11268) Altogen Biosystems offers the 293T/17 Transfection Reagent among a host of.
Products > Transfection Reagent for BMS/BMS2 Cells (Bone Marrow Cells) Altogen Biosystems offers the BMS2 Transfection Reagent among a host of 100+ cell.
Products > U87 Transfection Reagent (Glioblastoma Cells) Altogen Biosystems offers the U87 Transfection Reagent among a host of 100+ cell line specific.
Targeting of reactive oxygen species can be a potential therapeutic strategy for cancer treatment Ying-Ray Lee 1, San-Yuan Chen 2, and Hau-Ren Chen 3 1.
Products > PC-3 Transfection Reagent (Prostate Cancer Cells) Altogen Biosystems offers the PC-3 Transfection Reagent among a host of 100+ cell line specific.
Altogen Biosystems offers the 786-O Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection Kits. 786-O Transfection Reagent.
Products > Astrocyte Transfection Reagent (Primary Astrocyte Cells, Astroglia) Altogen Biosystems offers the Astrocyte Cell Transfection Reagent among.
Products > Transfection Reagent for C6 Cells (Glioma Cells, CCL-107) Altogen Biosystems offers the C6 Transfection Reagent among a host of 100+ cell line.
Products > 3T3-L1 Transfection Reagent (Embryonic Fibroblast Cells, CL-173) Altogen Biosystems offers the 3T3-L1 Transfection Reagent among a host of 100+
Products > AGS Transfection Reagent (Gastric Adenocarcinoma, CRL1739) Altogen Biosystems offers the AGS Transfection Reagent among a host of 100+ cell.
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > T98G Transfection Reagent (Glioblastoma Cells, CRL-1690)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > NCI-H1299 Transfection Reagent (Lung Adenocarcinoma)
Products > HT-1080 Transfection Reagent (Fibrosarcoma Cells)
Products > DLD-1 Transfection Reagent (Colon Cancer, CCL-221)
Products > SK-BR-3 Transfection Reagent (Breast Adenocarcinoma)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > 4T1 Transfection Reagent (Breast Cancer Cells, CRL-2539)
Renal Cell Carcinoma: Evaluation of the mitochondrial long non-coding RNA as potential targets for therapy Borgna V.1,2,3, Peña E5, Rivas A1,2,4, Araya.
Products > SK-MEL-28 Transfection Reagent (Melanoma Cells, HTB72)
Products > LoVo Transfection Reagent (Colon Adenocarcinoma)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > BT-20 Transfection Reagent (Breast Carcinoma Cells)
Products > PC-12 Transfection Reagent (Rat Pheochromocytoma Cells)
Products > AsPC-1 Transfection Reagent (Pancreatic Beta Cells)
Products > HUH-7 Transfection Reagent (Liver Cancer Cells)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > A375 Transfection Reagent (Melanoma Cells, CRL-1619)
Keloid Fibroblasts Resist Ceramide-Induced Apoptosis by Overexpression of Insulin- Like Growth Factor I Receptor  Hiroshi Ishihara, Hiroshi Yoshimoto,
Products > HeLa Transfection Reagent (Cervix Adenocarcinoma Cells)
Products > ZR-75-1 Transfection Reagent (Breast Carcinoma, CRL1500)
Products > NCI-H358 Transfection Reagent (Bronchioalveolar Cells)
Products > NCI-H23 Transfection Reagent (Lung Adenocarcinoma)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > LS-174T Transfection Reagent (Colon Adenocarcinoma)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Arsenic Induces Tumor Necrosis Factor α Release and Tumor Necrosis Factor Receptor 1 Signaling in T Helper Cell Apoptosis  Hsin-Su Yu, Gwo-Shing Chen 
Volume 17, Issue 2, Pages (February 2009)
Products > CLBPEC Transfection Reagent (Neuroblastoma Cells)
Bcl-2 and bcl-xL Antisense Oligonucleotides Induce Apoptosis in Melanoma Cells of Different Clinical Stages  Robert A. Olie, Christoph Hafner, Renzo Küttel,
Volume 24, Issue 10, Pages (October 2016)
Presentation transcript:

Abstract Glioblastoma multiforme (GBM) is the most common brain cancer of middle aged Americans. Unfortunately, survival rates are typically less than 1 year from time of diagnosis. Following surgery, GBM patients typically endure chemical and radiotherapies to slow tumor regrowth. Research suggests that under these treatments GBM cells regress by entering apoptosis, or programmed cell death. We investigated the use of small interfering RNAs (siRNAs) to induce apoptosis in human GBM cells in vitro. Current research suggests that siRNAs eliminate a particular target protein from a cell by degrading the target’s mRNA cellular pool. Bcl-2 is an anti-apoptotic protein in cells. Using Bcl-2 targeted siRNAs, we attempted to eliminate Bcl-2 from U87mg (human GBM) cells, cultured in vitro, inducing them into apoptosis. Preliminary data suggests that U87mg cell number is reduced (cell death enhanced) when treated with Bcl-2 siRNA compared to U87mg control cells, treated with a scrambled siRNA sequence. Introduction Glioblastoma multiforme (GBM) is the most common brain cancer among middle aged Americans and has a mean survival rate of approximately one-year (Julien et al. 2000). Cancer is the unregulated growth and proliferation of cells. Cell growth is a process normally controlled by apoptosis. Apoptosis is programmed cell death brought on by a variety of stimuli. This process involves decreased cell volume, modification of the cytoskeleton and degradation of DNA. After this occurs the cell releases tiny membrane-bound apoptotic bodies containing intact organelles that are quickly phagocitized. A new set of oncogenes is being defined that affect this apoptotic pathway (Julien et al. 2000). One of these is the Bcl-2 gene. Bcl-2 does not necessarily affect proliferation but it does inhibit apoptosis (Reed 1994). Bcl-2 has been found to be overexpressed in GBM (Julien et al. 2000). Not only does Bcl-2 affect apoptosis but also increased production of the gene has been found to increase resistance to chemotherapies and radiation treatment, therapies aimed at inducing apoptosis (Reed 1994). Inducing Apoptosis of Glioblastoma Multiforme Cells Using a Bcl-2 Specific siRNA Sequence Valerie P. Capozziello* and Jeffrey P. Thompson York College of Pennsylvania, Department of Biological Sciences Objective This research aims to investigate the use of siRNAs to downregulate the expression of the Bcl-2 gene and thereby induce apoptosis of U87MG Human GBM cells (Figure 1). Materials and Methods The suppression of genes by siRNA is a pathway that begins with double-stranded RNA (dsRNA) and is a two-step process (Figure 2). RNA interference (RNAi) machinery detects dsRNA and breaks it into approximately nucleotide long segments. These segments are bound in an RNA-protein complex that mediates the detection and destruction of mRNAs containing the same sequence as the dsRNA (Pierce 2002). Figure 2. Experiments Aseptically transferred 4x10 5 dilution of U87MG cells into a 96-well cell culture plate Transfected cells with siRNA and Transmessenger Transfection reagent complex Optimization reaction was performed to access the correct ratio of siRNA to TransMessenger to allow the most transfection Target sequence experimental siRNA and scrambled sequence control siRNA were used along with cells untreated with siRNA Efficiency of transfection was measured by reading the fluorescence of the cells after incubation with siRNA complexes Cells were transfected with siRNA and Transmessenger Transfection Reagent complexes at optimal ratio with a larger sample size Transfection was accessed in target sequence and scrambled sequence cells Cell viability was accessed by incubating cells with cell proliferation reagent PMS-MTS Change in absorbance of the reagent quantified amount of cell viability Standardized cell viability to amount of transfection to calculate cell death using the following calculation Absorbance of control– Absorbance of experimental Fluorescent units Sequence specific siRNAs can now be readily ordered to match a particular part of a gene sequence. Instructions for picking a fragment were obtained from xeragon.com, the same company from which the siRNAs were ordered. The target sequence was verified to be found in the Bcl-2 gene and not in any other gene sequence. The gene fragment of the Bcl-2 gene 5’-AACATCGGCCCTGTGGATGACTG-3’ was chosen according to those guidelines. In addition, siRNA was tagged with flourescein on the 3’-end, during synthesis by the company, for identification and quantification of transfection. Results 1.Optimal concentration of siRNA to Transmessenger Transfection reagent was 1:12 for both the target sequence and the scrambled sequence (Figure 3). 2.Transfection efficiency was greater in the scrambled versus target sequence. 3.Target sequence caused approximately three times the amount of cell death compared to scrambled sequence (Figure 4). 4.Standardization was required because of differing amounts of transfection between target and scrambled sequence. Discussion This data suggests that the siRNA mechanism is a possible method to induce cell death in human GBM cells. Efficiency of transfection is affected by ratio of siRNA to Transmessenger Transfection reagent and this must be optimized. Amount of transfection was also affected by differing uptake by cells even though they were presented with the complexes in the same manner. This is why standardization of cell death was required. Further study is needed to determine whether the observed death is due to apoptosis. Future Directions 1.Perform Western blot to determine if there is a decrease in the Bcl-2 protein level. 2. Determine if death is through apoptosis by looking for apoptotic markers. Literature Cited Accessed 9/9/ Accessed 9/9/2002 Julien, T., Frankel, B., Longo, S., Kyle, M., Gibson, S., Shillitoe, E., and Ryken, T Antisense-mediated inhibition of the Bcl-2 gene induces apoptosis in the human malignant glioma. Surgical Neurology. 53: Pierce, J.L RNAi turns the message off.The Scientist. 16:44-6. Reed, J.C Bcl-2 and the regulation of programmed cell death. The Journal of Cell Biology. 124:1-6. Figure 1. Figure 1. U87MG Human GBM cells. Figure 2. siRNA mechanism of gene suppression. Figure 3. Mean fluorescence of U87MG cells after transfection. Three ratios of siRNA to Transmessenger Transfection reagent were studied for both the target and scrambled sequence. The 1:12 ratio had the highest transfection rate in both cases. Figure 4. Calculated amount of cell death in U87MG cells after transfection and cell viability assay. Acknowledgments The Pennsylvania Academy of Science for funding